Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China Authors: Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao, Jisheng Li Published: 2026 ABSTRACT AbstractBackground:The FLAURA2 and MARIPOSA trials established survival benefits of osimertinib plus chemotherapy and amivantamab plus lazertinib, respectively, over osimertinib monotherapy in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitizing mutation.Objectives:This study aimed to evaluate the cost-effectiveness of osimertinib plus chemotherapy versus amivantamab plus lazertinib from the US and Chinese healthcare perspectives.Design:An economic evaluation.Methods:A partitioned survival model with 28-day cycles was developed to simulate total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) over a 10-year time horizon. Clinical efficacy and safety inputs were derived from FLAURA2 and MARIPOSA. Costs and utilities were sourced from public bid-winning databases, local charges, and published literature. A scenario analysis incorporated the amivantamab patient assistance program (PAP) in China. One-way and probabilistic sensitivity analyses (OWSA, PSA) assessed model uncertainty.Results:Compared with osimertinib monotherapy, the ICERs for osimertinib plus chemotherapy were $551,944/QALY (US) and $37,965/QALY (China). For amivantamab plus lazertinib, ICERs were $2,186,499/QALY (US) and $291,478/QALY (China). OWSA identified drug prices and utility values as key drivers. PSA indicated that in the US, osimertinib was cost-effective in 100% of simulations at a $150,000/QALY threshold. In China, at a $41,983.66/QALY threshold, osimertinib plus chemotherapy had a 74.10% probability of being cost-effective. The PAP scenario did not alter the conclusion for amivantamab plus lazertinib in China.Conclusion:Based on indirect comparisons, osimertinib monotherapy is the cost-effective option for advanced EGFR-mutant NSCLC in the US. In China, osimertinib plus chemotherapy represents the optimal regimen given current pricing.Keywords: amivantamab, cost-effectiveness, epidermal growth factor receptor mutation, non-small cell lung cancer, osimertinib Background Lung cancer remains a leading cause of global cancer incidence and mortality.1,2 Non-small cell lung cancer (NSCLC) constitutes about 85% of cases, with approximately 60% diagnosed at an advanced stage and a poor 5-year survival rate of 18%, imposing a substantial disease and economic burden worldwide. 3 Epidermal growth factor receptor (EGFR) mutations are key oncogenic drivers, present in 10%–15% of Western and 30%–40% of Asian NSCLC patients.4,5 While third-generation EGFR-tyrosine kinase inhibitors (TKIs) have become the standard first-line therapy for advanced EGFR-mutant NSCLC, 6 and are indicated for those harboring sensitizing EGFR mutations (exon 19 deletions or L858R point mutations) with stage IIIB/IIIC unresectable or stage IV metastatic disease, including those with stable asymptomatic brain metastases, the development of drug resistance inevitably limits long-term efficacy.7,8 Consequently, there is an urgent clinical need for novel treatment strategies to delay the emergence of acquired resistance and further improve patient survival. The third-generation EGFR-TKI osimertinib has been investigated in novel combination regimens with promising efficacy. 9 In the phase III FLAURA2 trial, treatment-naïve patients with advanced EGFR-mutant NSCLC receiving osimertinib plus chemotherapy showed significantly prolonged progression-free survival (PFS) and OS compared with osimertinib monotherapy (PFS: 25.5 vs 16.7 months, hazard ratio (HR) 0.62, 95% confidence interval (CI): 0.49–0.79; OS: 47.5 vs 37.6 months, HR 0.77, 95% CI: 0.61–0.96, p = 0.02).10,11 Meanwhile, amivantamab, a bispecific antibody targeting EGFR and MET receptors, inhibits both signaling pathways and exhibits antitumor activity. 12 Lazertinib, a third-generation EGFR-TKI, showed favorable efficacy and tolerability in the phase III MARIPOSA trial. 13 Compared with osimertinib monotherapy, amivantamab plus lazertinib significantly improved both PFS (23.7 vs 16.6 months, HR 0.70, 95% CI: 0.58–0.85, p < 0.001) and OS (estimated >4 years vs 36.7 months, HR 0.75, 95% CI: 0.61–0.92, p < 0.005) in patients with EGFR exon 19 del or L858R mutations. Furthermore, both combination regimens have demonstrated superior efficacy compared with osimertinib monotherapy in high-risk patients with baseline brain metastases or TP53 co-mutations.14,15 Both the osimertinib plus chemotherapy and amivantamab plus lazertinib regimens are now recommended by U.S. and Chinese clinical guidelines for advanced EGFR-mutant NSCLC, confirming their clinical efficacy.16,17 However, their substantially higher costs compared to osimertinib monotherapy pose a significant economic challenge to healthcare systems.18,19 This study aimed to assess the cost-effectiveness of these two combination regimens from the healthcare system perspectives of the United States and China, using data from the FLAURA2 and MARIPOSA trials. The findings are intended to provide evidence-based guidance for clinical treatment selection and to support healthcare policymakers in budget planning and resource allocation for advanced EGFR-mutant NSCLC. Materials and methods This economic evaluation was based on modeling techniques, price databases, and published literature, so ethics committee approval was exempted. Methodology adhered to the consolidated health economic evaluation reporting standards 2022 (CHEERS 2022; Supplemental Table 1). 20 Per the designs of the FLAURA2 and MARIPOSA trials, eligible patients had histologically confirmed, previously untreated locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations.10,14 Patients were randomized to receive osimertinib plus chemotherapy, amivantamab plus lazertinib, or osimertinib monotherapy. Osimertinib (80 mg daily) or lazertinib (240 mg daily) was administered orally until disease progression.10,14 In the chemotherapy cohort, patients received pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC 5) on day 1 of each 21‑day cycle for four induction cycles, followed by maintenance pemetrexed (500 mg/m2 every 3 weeks) until progression. 10 Amivantamab was administered intravenously at 1050 mg (or 1400 mg for body weight ⩾80 kg) weekly during the first 4‑week cycle, then every 2 weeks thereafter. 14 To assess long‑term cost‑effectiveness, our model assumed that patients received common subsequent therapies after progression, including platinum‑based doublets with pemetrexed or paclitaxel, with or without bevacizumab, given that detailed regimens and duration of subsequent treatment were not reported in either the MARIPOSA or FLAURA2 trial. Model structure We constructed a partitioned survival model incorporating three health states, in which state occupancy was directly estimated from PFS and OS curves, to measure the costs, life-years (LYs), and quality-adjusted life-years (QALYs) associated with osimertinib plus chemotherapy, amivantamab plus lazertinib, and osimertinib alone as first-line treatments for advanced EGFR-mutant NSCLC in China and the US. The model comprised three mutually exclusive health states: PFS, progressive disease (PD), and death (Figure 1). Reflecting the natural progression of advanced NSCLC, all patients entered the model in the PFS state, with permissible transitions only to PD or death. The proportion of patients in the PFS and PD health states was derived from the area under the Kaplan–Meier curves for PFS and OS from the MARIPOSA and FLAURA2 trials. A cycle length of 28 days and a 10-year time horizon were adopted. Incremental cost-effectiveness ratios (ICERs) were calculated by dividing the difference in costs between non-dominated treatment strategies by the difference in QALYs. Costs and outcomes were discounted annually at 5% in China and 3% in the United States, with half-cycle correction applied in accordance with the Chinese Pharmacoeconomic Evaluation Guidelines. 21 All costs were converted to 2025 US dollars using an average exchange rate of 1 USD = 7.1217 CNY. Willingness-to-pay (WTP) thresholds were defined as three times the 2025 per capita GDP ($41,983.66/QALY) in China and $150,000 per QALY in the US. 22 The structure of the partitioned survival model. Clinical inputs The PFS and OS data were obtained from the published clinical efficacy results of the FLAURA2 and MARIPOSA trials. GetData Graph Digitizer 2.26 was employed to extract data points for estimating individual patient data. Seven parametric survival models were used to fit survival curves of different treatment strategies, including exponential, Weibull, gamma, generalized gamma, Gompertz, log-normal, and log-logistic models. 23 Model selection was guided by the Akaike information criterion, Bayesian information criterion, visual inspection, and clinical plausibility. 24 As the proportional hazards assumptions were not fully satisfied (Supplemental Figures 1–4), the survival data of osimertinib were estimated as the average of the FLAURA2 and MARIPOSA trials. Survival analysis was conducted using R software (v4.3.2; R Foundation for Statistical Computing, Vienna, Austria). According to the International Society of Pharmacoeconomics and Outcomes Research-Society of Medical Decision Making Task Force Report on Model Transparency and Validation, face validity was assessed by two empirical clinicians, and internal validity was evaluated through extreme parameter and substantive coding verification. 25 More details are provided in Supplemental Table 2 and Supplemental Figures 5–12. Cost inputs This study primarily examined direct medical costs associated with treatment phases in Chinese and US patients. These costs included multiple components, such as first-line and subsequent drug costs, imaging examination costs, end-of-life care costs, best supportive care costs, and adverse event (AE) management costs. Drug costs were extracted from the YaoZH database (https://data.yaozh.com/) and the Department of Veterans Affairs. Drug dosages were estimated using a BSA of 1.72 m2 and a body weight of 65 kg in China, and 1.86 m2 and 70 kg in the US. 26 The dosage of amivantamab was weight-adjusted based on the MARIPOSA trial, with 88% of patients weighing <80 kg and 12% weighing ⩾80 kg. All patients were assumed to undergo imaging and laboratory examinations every 6 months. As the grade 1–2 AEs could be manageable with standard monitoring, only grade 3–4 AEs with an incidence of 5% or more were calculated in the model, including paronychia, rash, hypoalbuminemia, increased alanine aminotransferase level, dermatitis acneiform, anemia, pulmonary embolism, neutropenia, and thrombocytopenia, with unit costs derived from published literature.19,27–29 Other costs were derived from previously published literature and adjusted to 2025 using the consumer price index for healthcare services.19,30–33 The costs and utilities are presented in Supplemental Tables 3 and 4. Health state utilities Each health state was assigned a health utility value anchored at 0 (death) and 1 (perfect health). 34 The health state utility values for PFS and PD were derived from two cross-sectional studies, assessed using the EuroQol five-dimensional instrument. The utility values for PFS and PD states during treatment were 0.70 and 0.58 in the United States, and 0.86 and 0.77 in China, respectively.34,35 The disutility values associated with grade ⩾3 AEs were estimated based on published literature.19,31–33,36,37 All costs and utilities are presented in Supplemental Tables 3 and 4. Sensitivity and scenario analyses To assess the potential uncertainty of the results, one-way and probabilistic sensitivity analyses (PSA) were performed for all input parameters. In the one-way sensitivity analysis (OWSA), the parameter ranges for the model parameters were based on either 95% CI or assuming a 20% change from the base-case value to explore the impact of each parameter on the ICER. In the PSA, a Monte Carlo simulation with 10,000 iterations was generated by simultaneously varying parameters according to prespecified statistical distributions. The beta distribution was applied to AE incidence and utility values, while the gamma distribution was used for costs, body weight, and BSA. The cost-effectiveness acceptability curves were generated to illustrate the preferred treatment regimen under various WTP thresholds. Scenario analyses First, we constructed a partitioned survival model based on network meta-analysis. Second, we increased the frequency of imaging and laboratory tests from every 6 months to every 3 months. In addition, given the existence of medical insurance policies and patient assistance programs (PAPs) provided by pharmaceutical companies in China, scenario analyses were conducted to account for these factors. In China, a PAP was launched in June 2025 for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations who receive treatment with amivantamab plus lazertinib. Initiated by the China Cancer Foundation in collaboration with the pharmaceutical company Janssen, this program offers a drug assistance policy of “purchasing 2 cycles with 2 cycles free,” followed by “purchasing 1 cycle with 1 cycle free.” To better reflect the real-world clinical application of the drug in China, this study incorporated the PAP patient into the cost-effectiveness analysis. Results Base-case results At a 10-year time horizon, osimertinib, osimertinib plus chemotherapy, and amivantamab plus lazertinib were associated with average costs of $455,033.06, $757,230.58, and $1,427,288.25, and gained QALYs of 2.34, 2.88, and 2.78 in the US, respectively. The three treatment regimens yielded lower costs and higher QALYs in China versus the US. Compared with osimertinib, the ICERs of osimertinib plus chemotherapy and amivantamab plus lazertinib were $551,943.84 and $2,186,498.76 per QALY in the US, and $37,965.20 and $291,477.71 per QALY in China, respectively (Table 1). Table 1.Base-case results.StrategyCosts, $LYsQALYsICER ($/LY)ICER ($/QALY)The US Osimertinib455,033.063.912.34–– Osimertinib plus chemotherapy757,230.584.792.88342,830.38–551,943.84– Amivantamab plus lazertinib1,427,288.254.732.781,179,297.62Dominated2,186,498.76DominatedChina Osimertinib39,164.163.912.80–– Osimertinib plus chemotherapy61,590.614.793.3925,441.87–37,965.20– Amivantamab plus lazertinib186,032.414.733.30178,143.95Dominated291,477.71DominatedICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year. Base-case results. ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year. Sensitivity analyses The results of OWSA indicated that the costs of osimertinib and amivantamab were the most influential parameters affecting the ICERs in the US, whereas in China, the utility value of PFS state and the cost of amivantamab exhibited the greatest impact (Figure 2). Notably, in the US, none of the parameters significantly altered the base-case results. In contrast, the cost of osimertinib might significantly alter the ICER in China, with the lowest and highest ICERs for osimertinib plus chemotherapy being $31,005.51 per QALY and $51,784.74 per QALY compared to osimertinib, respectively. The cost-effectiveness acceptability curves were presented in Figure 3. At current prices and WTP thresholds, osimertinib and osimertinib plus chemotherapy were the preferred treatment options for previously untreated advanced EGFR-mutant NSCLC in the US and China, respectively, with cost-effectiveness probabilities of 100% and 74.10%, respectively (Figure 3). One-way sensitivity analysis results of osimertinib plus chemotherapy (a, c) and amivantamab plus lazertinib (b, d) compared with osimertinib in the US and China, respectively. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; PD, progressive disease; PFS, progression-free survival. The cost-effectiveness acceptability curves in the US (a) and China (b). Scenario analysis The partitioned survival model, constructed based on the network meta-analysis, demonstrated that the primary findings remained robust. Specifically, osimertinib plus chemotherapy and osimertinib continued to represent the most cost-effective therapeutic options in China and the US, respectively (Supplemental Table 5). Adjusting the imaging and laboratory monitoring interval from 6 to 3 months resulted in a marginal rise in the ICER for osimertinib plus chemotherapy and amivantamab plus lazertinib compared with osimertinib (Supplemental Table 6). After incorporating the relevant PAPs into the model, the ICER for amivantamab plus lazertinib was significantly reduced to $82,318.09 per LY and $134,688.20 per QALY; however, osimertinib plus chemotherapy still represented a high-value option with lower costs and higher QALYs (Supplemental Table 7). Discussion With the emergence of combination strategies aimed at delaying resistance and prolonging survival, first-line treatment paradigms for EGFR-mutant advanced NSCLC are undergoing substantial evolution.10,11,14,15 Leveraging efficacy data from the FLAURA2 and MARIPOSA trials, this study represents the first comprehensive cost-effectiveness comparison of osimertinib plus chemotherapy and amivantamab plus lazertinib versus osimertinib monotherapy from both the Chinese and US healthcare system perspectives. Our findings demonstrate marked cross-country heterogeneity: osimertinib monotherapy may be the most cost-effective option in the US, whereas osimertinib plus chemotherapy emerges as the preferred strategy in China. The results should be interpreted with caution; the preferred regimen still requires further validation through head-to-head clinical trials. The divergence in optimal treatment strategies between China and the US is primarily driven by fundamental differences in drug pricing and reimbursement mechanisms. Since the establishment of the National Healthcare Security Administration in 2017, China has implemented a centralized national reimbursement negotiation system that substantially reduces the prices of innovative anticancer drugs through volume-based procurement and multi-round price negotiations, thereby markedly improving their economic value and affordability.38,39 Under this framework, osimertinib was incorporated into the National Reimbursement Drug List in 2021 for the treatment of locally advanced or metastatic EGFR-mutant NSCLC, including exon 19 deletion, L858R, and T790M mutations, with negotiated price reductions exceeding 80% compared with original list prices. 40 This policy-driven price adjustment plays a decisive role in bringing the ICER of osimertinib plus chemotherapy within the Chinese WTP threshold. In contrast, the US healthcare system relies largely on market-based pricing with limited centralized negotiation, resulting in substantially higher drug acquisition costs that offset incremental survival benefits and render combination regimens economically unfavorable. Supporting this interpretation, multiple economic evaluations conducted under negotiated or real-world pricing scenarios have demonstrated that osimertinib-based combination strategies may achieve acceptable cost-effectiveness in China across different clinical settings. 41 Beyond base-case analyses, scenario and sensitivity analyses provide important insights into the real-world applicability of high-cost combination regimens. In China, incorporation of the amivantamab PAP substantially reduced the incremental costs of amivantamab plus lazertinib; however, the regimen remained not cost-effective and was still dominated by osimertinib plus chemotherapy under the national WTP threshold. This finding suggests that short-term or partial cost-offset strategies, such as PAPs, may alleviate financial burden at the individual level but are insufficient to fundamentally alter long-term cost-effectiveness when sustained drug acquisition costs remain high. OWSA further identified drug prices and PFS utility values as the most influential parameters across both healthcare settings, highlighting that economic value is highly sensitive to pricing strategies and patient-reported quality of life during extended PFS. From a clinical perspective, although combination therapies offer meaningful survival benefits, their increased treatment intensity and toxicity profiles may attenuate quality-of-life gains, partially offsetting improvements in survival outcomes. These results underscore the importance of integrating health-related quality of life and affordability considerations into treatment selection, and suggest that future optimization of combination strategies should focus not only on prolonging survival but also on improving tolerability and achieving sustainable pricing to enhance overall value in routine clinical practice. Our findings were largely consistent with, yet extended, existing pharmacoeconomic evidence. From the US healthcare system perspective, Tian et al. 18 constructed a Markov model to evaluate osimertinib plus chemotherapy as first-line treatment for advanced EGFR-mutant NSCLC and reported an ICER of $223,727.1 per QALY compared with osimertinib monotherapy, indicating that the combination regimen was not cost-effective. Our results corroborated this conclusion in the US setting. In China, Shu et al. 41 similarly found that osimertinib plus chemotherapy might not be cost-effective under earlier pricing assumptions. In contrast, our analysis demonstrated that osimertinib plus chemotherapy has emerged as the preferred first-line option in China, a discrepancy that is likely attributable to the substantial reduction in osimertinib prices over the past 2 years following reimbursement policy adjustments. With respect to amivantamab-based strategies, available evidence consistently suggests a lack of cost-effectiveness across healthcare systems. Wu et al. reported ICERs of $563,602.3 per QALY in the US and $214,195.51 per QALY in China for amivantamab plus lazertinib versus osimertinib, while Zhang et al. 42 further showed that neither amivantamab plus lazertinib nor lazertinib monotherapy constituted a cost-effective first-line option for EGFR exon 20 insertion mutations positive NSCLC in China. Collectively, these findings highlight that although clinical efficacy remains fundamental, drug pricing dynamics and reimbursement policies play a decisive role in shaping the economic value of novel combination regimens. Our model has some limitations. First, in the absence of direct head-to-head trials comparing osimertinib plus chemotherapy with amivantamab plus lazertinib, clinical inputs were sourced from the FLAURA2 and MARIPOSA trials. Minor differences in baseline patient characteristics between trials could have influenced model outcomes. Second, only grade 3–4 AEs with an incidence of 5% or more were included in cost and disutility estimates, as lower-grade events are generally manageable through routine monitoring. This approach aligns with standard pharmacoeconomic practice and avoids potential double-counting of costs or disutilities. Finally, we estimated subsequent costs based on the most frequently prescribed regimens recommended by Chinese Society of Clinical Oncology (CSCO) and National Comprehensive Cancer Network (NCCN) guidelines; however, a potential discrepancy may exist between these estimates and real-world expenditure. Despite these limitations, the model provides valuable insights to guide clinical decision-making and inform reimbursement policy for first-line treatment of EGFR-mutant advanced NSCLC. Conclusion Based on indirect comparisons of survival data from the FLAURA2 and MARIPOSA trials, our study shows that osimertinib monotherapy may be the most cost-effective first-line treatment for EGFR-mutant advanced NSCLC in the US, whereas osimertinib plus chemotherapy is preferred in China. These findings highlight that local drug pricing, reimbursement policies, and quality-of-life outcomes critically determine the economic value of novel combination regimens. Integrating clinical efficacy with affordability and patient-centered considerations is essential to guide optimal, value-based treatment decisions. Supplemental Material sj-pdf-1-tam-10.1177_17588359261465356 – Supplemental material for Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China Supplemental material, sj-pdf-1-tam-10.1177_17588359261465356 for Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China by Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao and Jisheng Li in Therapeutic Advances in Medical Oncology Acknowledgments None. Footnotes ORCID iDs: Shixian Liu https://orcid.org/0000-0003-1445-4057 Wen Zhao https://orcid.org/0000-0003-1077-4424 Jisheng Li https://orcid.org/0000-0002-4186-6228 Supplemental material: Supplemental material for this article is available online. Contributor Information Yihong Guo, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Shixian Liu, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China; Center for Health Management and Policy Research, Shandong University (Shandong Provincial Key New Think Tank), Jinan, China. Chuang Yang, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Chengjun Wang, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Rongyu Zhang, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Yunfei Wang, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Yanan Song, Cheeloo College of Medicine, Shandong University, Jinan, China. Mingfei Liu, Cheeloo College of Medicine, Shandong University, Jinan, China. Ruolin Zhang, Cheeloo College of Medicine, Shandong University, Jinan, China. Tiantian Xuan, Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China. Wen Zhao, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China. Jisheng Li, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China. Declarations Ethics approval and consent to participate: This economic evaluation was based on modeling techniques, price databases, and published literature, so ethics committee approval was exempted. Consent for publication: Not applicable. Author contributions: Yihong Guo: Methodology; Writing – original draft. Shixian Liu: Data curation; Methodology; Visualization; Writing – original draft; Writing – review & editing. Chuang Yang: Methodology; Validation; Writing – original draft. Chengjun Wang: Methodology; Validation; Writing – review & editing. Rongyu Zhang: Methodology; Validation; Writing – review & editing. Yunfei Wang: Methodology; Validation; Writing – review & editing. Yanan Song: Methodology; Validation; Writing – review & editing. Mingfei Liu: Methodology; Validation; Writing – review & editing. Ruolin Zhang: Methodology; Validation; Writing – review & editing. Tiantian Xuan: Methodology; Supervision; Writing – review & editing. Wen Zhao: Methodology; Supervision; Writing – original draft; Writing – review & editing. Jisheng Li: Methodology; Supervision; Writing – review & editing. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Natural Science Foundation of Shandong Province (ZR2020LZL018), National Natural Science Foundation of China (82303749), and the Natural Science Foundation of Shandong Province (ZR2023QH292). The authors declare that there is no conflict of interest. Availability of data and materials: All data generated or analyzed during this study were included in the manuscript and Supplemental Files. References Associated Data Supplementary Materials sj-pdf-1-tam-10.1177_17588359261465356 – Supplemental material for Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China Supplemental material, sj-pdf-1-tam-10.1177_17588359261465356 for Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China by Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao and Jisheng Li in Therapeutic Advances in Medical Oncology